A detailed history of Crewe Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 1,670 shares of GILD stock, worth $147,093. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,670
Previous 1,924 13.2%
Holding current value
$147,093
Previous $140,000 18.57%
% of portfolio
0.01%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$63.15 - $72.88 $16,040 - $18,511
-254 Reduced 13.2%
1,670 $114,000
Q1 2024

May 13, 2024

BUY
$71.58 - $87.29 $137,719 - $167,945
1,924 New
1,924 $140,000
Q2 2023

Jul 28, 2023

SELL
$76.01 - $86.7 $6,460 - $7,369
-85 Reduced 6.98%
1,133 $87,000
Q1 2023

May 12, 2023

SELL
$77.31 - $88.08 $10,050 - $11,450
-130 Reduced 9.64%
1,218 $101,000
Q4 2022

Feb 07, 2023

SELL
$62.32 - $89.47 $21,936 - $31,493
-352 Reduced 20.71%
1,348 $115,000
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $40,308 - $46,042
677 Added 66.18%
1,700 $105,000
Q2 2022

Aug 02, 2022

BUY
$57.72 - $65.01 $4,213 - $4,745
73 Added 7.68%
1,023 $63,000
Q1 2022

Apr 27, 2022

SELL
$57.92 - $72.58 $347 - $435
-6 Reduced 0.63%
950 $56,000
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $62,025 - $70,399
956 New
956 $69,000
Q4 2020

Jan 27, 2021

SELL
$56.65 - $64.55 $3,399 - $3,873
-60 Closed
0 $0
Q3 2020

Oct 13, 2020

BUY
$62.1 - $78.08 $3,726 - $4,684
60 New
60 $4,000
Q4 2019

Feb 05, 2020

SELL
$61.62 - $67.78 $25,695 - $28,264
-417 Closed
0 $0
Q4 2018

Feb 05, 2019

SELL
$60.54 - $79.0 $24,216 - $31,600
-400 Reduced 48.96%
417 $26,000
Q4 2017

Feb 09, 2018

BUY
$71.15 - $83.52 $58,129 - $68,235
817
817 $59,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.